{ "ProductData": { "ID": "3.1.1.2.13.1", "ProductType": "Others", "BrandName": "α-2,3-Sialyltransferase, rec.", "ProductNameAddition": "human, expressed in HEK-293F, solution", "RegulatoryDisclaimer1": "For life science research only. Not for use in diagnostic procedures.", "DisclaimerGroup1": "LSR", "RegulatoryDisclaimer2": null, "DisclaimerGroup2": null, "RegulatoryDisclaimer3": null, "SampleType": [ ], "LicenseDisclaimers": [ { "Identifier": "1403506419168", "LongText": "The sale of the Product does not exhaust or grant any rights in third party patents including patents of companies of the F. Hoffmann - La Roche AG group of companies, in particular, for the use of modified antibodies obtained by using the product.", "Order": "78" } ], "RelatedLinks": "", "Clone": "", "ControlTissue": [ "" ], "ISOtypes": "", "Species": [ "" ], "StainLocalization": [ "" ], "ProductNameGlobal": "alpha-2 3-Sialyltransferase rec." }, "ProductImageDetails": { "ImagePath": "https://pim-media.roche.com/Images/CB_IMAGE_.png", "ImageType": "Image main" }, "Product2Taxonomy": { "Product2TaxonomyReferences": [ { "StructureSystemIdentifier": "Product_Grouping", "StructureSystemName": "Product Grouping", "NodeID": "02-0052", "StructureNodeStatus": "valid", "NodeName": "In vitro Glycoengineering" }, { "StructureSystemIdentifier": "OWP_Product_Types", "StructureSystemName": "Product Types", "NodeID": "70-025-00", "StructureNodeStatus": "valid", "NodeName": "Glycosyltransferases" }, { "StructureSystemIdentifier": "OWP_Organization", "StructureSystemName": "Organization", "NodeID": "01-01-01-07-00", "StructureNodeStatus": "valid", "NodeName": "CustomBiotech and LifeScience" }, { "StructureSystemIdentifier": "Product_Grouping", "StructureSystemName": "Product Grouping", "NodeID": "02-0014", "StructureNodeStatus": "valid", "NodeName": "Enzymes" }, { "StructureSystemIdentifier": "Product_Solutions", "StructureSystemName": "Product Solutions", "NodeID": "520", "StructureNodeStatus": "valid", "NodeName": "CustomBiotech" }, { "StructureSystemIdentifier": "Lab_Type", "StructureSystemName": "Lab Types", "NodeID": "180-00", "StructureNodeStatus": "invalid", "NodeName": "" }, { "StructureSystemIdentifier": "Applications", "StructureSystemName": "Applications", "NodeID": "99-00-00", "StructureNodeStatus": "invalid", "NodeName": "" }, { "StructureSystemIdentifier": "OWP_Techniques", "StructureSystemName": "Techniques", "NodeID": "999-00", "StructureNodeStatus": "invalid", "NodeName": "" }, { "StructureSystemIdentifier": "Disease_Areas", "StructureSystemName": "Disease Areas", "NodeID": "99-00-00", "StructureNodeStatus": "invalid", "NodeName": "" }, { "StructureSystemIdentifier": "Pathogens", "StructureSystemName": "Pathogens", "NodeID": "99-00-00", "StructureNodeStatus": "invalid", "NodeName": "" }, { "StructureSystemIdentifier": "OWP_Family", "StructureSystemName": "Product Families", "NodeID": "999", "StructureNodeStatus": "invalid", "NodeName": "" }, { "StructureSystemIdentifier": "Health_Topics", "StructureSystemName": "Health Topics", "NodeID": "99-00-00", "StructureNodeStatus": "invalid", "NodeName": "" } ] }, "Product2Materials": { "P2MaterialReferences": [ { "MaterialNum": "07429916103", "MaterialDescription": "alpha-2,3-Sialyltransferase, rec.", "RegisteredProductName": "alpha-2,3-Sialyltransferase, rec.", "GTIN": "07613336130766", "ProductCategoryText": "Reagents, kits", "OldMaterialNumber": "", "PackSizePIM360": "custom fill", "PackSizeDescPIM360": "Not Available", "MaterialAnnotation": "CustomBiotech product. Please contact your local representative.", "ReadyForUse": "", "OrderInformation": "Unit of measure is \"mg\"." } ] }, "Product2Products": { "Product2ProductReference": [ ] }, "ProductSpec": [ { "ProductSpecVariant": { "Chapters": [ { "Name": "Molecular Weight", "Value": "34.5 kDa", "Language": "en", "Country": "XG", "Code": "Molecular Weight" }, { "Name": "Protocols", "Value": "Procedure and Assay Conditions

The optimal reaction conditions for sialylation of a target protein can be different for each application. Therefore, the presented protocol can only serve as a suggested starting protocol. Optimization of reaction conditions (e.g., with different enzyme-IgG-ratios) is recommended to determine the optimal conditions for each application.

1		Preparation of the reaction buffer, containing 6.1 mM CMP-NANA, 200 mM MES, pH 6.5. •Dissolve 40 mg CMP-NANA and 390.4 mg MES in 6 ml of water. •Adjust pH to 6.5. •Adjust to a final volume of 10 ml with water.
2		Setting up the sialylation reaction, containing 500 μg CMP-NANA, 100 mg ST3Gal-6, 1 mg IgG. Pipet the following solutions into a reaction tube: •125 μl reaction buffer •100 μl IgG (10 mg/ml, pH 6) •18 μl α-2,3-Sialyltransferase •7 μl water
3		Incubate the reaction at +37°C.
4		Stop the reaction by freezing the tube at -15 to -25°C.
5		Analyze the samples

It is recommended to set up several identical reactions and stop them at different time points (e.g., 2 h, 8 h, 24 h) to plot the kinetics for each application.


Analytics

Samples were analyzed by electrospray ionization mass spectrometry and the content of G2+0SA, G2+1SA, and G2+2SA N-glycans was determined.
Instrument: Synapt G2 HDMS device (Waters, UK)
Software: MassLynx V 4.1
 ", "Language": "en", "Country": "XG", "Code": "Protocols" }, { "Name": "CB - Order Information", "Value": "Unit of measure is \"mg\".", "Language": "en", "Country": "XG", "Code": "CB - Order Information" }, { "Name": "Results", "Value": "As an example, highly galactosylated humanized monoclonal antibodies IgG1 and IgG4 are used for the kinetics.

Kinetics of α-2,3-Sialytransferase with IgG1
Maximal biantennary sialylation of IgG1 is observed after 24 hours (G2 + 2SA).​Fig. 1: Time course of sialylation of IgG1 using 100 g recombinant ST3Gal-6 per mg IgG.
Kinetics of α-2,3-Sialytransferase with IgG4
Maximal biantennary sialylation of IgG4 is obtained after 8 hours (G2 + 2SA).", "Language": "en", "Country": "XG", "Code": "Results" }, { "Name": "Applications (IFU)", "Value": "For in vitro sialylation of all Galß1-4GlcNAc units on glycoproteins and complex molecules such as human monoclonal antibodies (MAB), use α-2,3-Sialyltransferase (ST3Gal-6) and CMP-N-Acetylneuraminic Acid (CMP-NANA).", "Language": "en", "Country": "XG", "Code": "Applications (IFU)" }, { "Name": "Content", "Value": "

Vial / Bottle	Label	Function / Description	Content
1	α-2,3-Sialyltransferase rec.	Enzyme Storage buffer contains 50 mM MES, 200 mM NaCl, pH 6.4 at +4°C	Solution

", "Language": "en", "Country": "XG", "Code": "Content" }, { "Name": "Quality Control", "Value": "No animal-derived material is added in fermentation, purification and final formulation of this enzyme.", "Language": "en", "Country": "XG", "Code": "Quality Control" }, { "Name": "Applications", "Value": "Incubation of α-2,3-Sialyltansferase and CMP-NANA with a glycoprotein leads to increased sialylation of the glycoprotein.

As α-2,3-Sialyltansferase rec. adds sialic acid only to galactosylated glycostructures, a galactosylation of the glycoprotein in a previous step helps to achieve higher sialylation levels. Galactosylation can be achieved by incubation of the target protein with ß-1,4-Galactosyltransferase and UDP-Galactose.", "Language": "en", "Country": "XG", "Code": "Applications" }, { "Name": "Positioning", "Value": "α-2,3-Sialyltransferase, rec. can be used for in vitro glycoengineering of glycoproteins, e.g. therapeutic proteins.", "Language": "en", "Country": "XG", "Code": "Positioning" }, { "Name": "Benefits", "Value": "Benefits of using in vitro glycoengineering to modify glycosylation of therapeutic proteins:

• Time- and cost-saving generation of glycan variants to facilitate drug development.
• Optimized glycosylation without compromising other CQAs or product yield.
• Improved lot-to-lot consistency to reduce risk of product quality variation and resulting delays.
• Generation of glycoprofiles which may not otherwise be generated.
• Streamlined analytics in comparability studies.

", "Language": "en", "Country": "XG", "Code": "Benefits" }, { "Name": "Product Description", "Value": "α-2,3-Sialyltansferase, rec. is a highly active recombinant human glycosyltransferase, expressed in HEK-293F.", "Language": "en", "Country": "XG", "Code": "Product Description" }, { "Name": "Specification", "Value": "Appearance: Clear, colorless to slightly colored solution.
Composition: 50 mM MES, 200 mM NaCl, pH 6.4 ± 0.1 at +4°C
Specific activity: ≥80 U/μg
Protein A280nm ( 1 mg/mL) = 0.877: 5.5 ± 0.5 mg/mL
Purity: ≥90%
Bioburden: ≤100 CFU/mL (in evaluation)
Endotoxin: ≤10 EU/mg (in evaluation)
Stability: At -15 to -25°C within specification range for 12 months.
", "Language": "en", "Country": "XG", "Code": "Specification" }, { "Name": "Properties", "Value": "Molar mass: 34.5 kDa by cDNA", "Language": "en", "Country": "XG", "Code": "Properties" } ] } } ] }